PTEN-deficient cancers depend on PIK3CB

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2008-09-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0802655105PMID 18755892PMCID PMC2529105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

  2008cited by this paper
• Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

  2008cited by this paper
• Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

  2008cited by this paper
• Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development

  2008cited by this paper
• A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

  2008cited by this paper
• Tenets of PTEN tumor suppression.

  2008influential reference
• Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

  2008cited by this paper
• Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy

  2007cited by this paper
• A new mutational AKTivation in the PI3K pathway.

  2007cited by this paper
• High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.

  2007cited by this paper
• PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma

  2007cited by this paper
• Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

  2007cited by this paper
• The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

  2006influential reference
• Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation

  2006cited by this paper
• PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target

  2006cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005influential reference
• Somatic mutation and gain of copy number of PIK3CA in human breast cancer

  2005cited by this paper
• Specific role for p85/p110beta in GTP-binding-protein-mediated activation of Akt.

  2005cited by this paper
• Colorectal cancer: Mutations in a signalling pathway

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

  2005cited by this paper
• Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice.

  2005cited by this paper
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

  2005cited by this paper
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

  2005cited by this paper
• PI 3-kinase p110β: a new target for antithrombotic therapy

  2005cited by this paper
• PI 3-kinase p110beta: a new target for antithrombotic therapy.

  2005cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• Selective role of PI3K delta in neutrophil inflammatory responses.

  2003cited by this paper
• Selective role of PI3Kδ in neutrophil inflammatory responses

  2003cited by this paper
• Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway

  2003cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice

  2002cited by this paper
• Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.

  2000cited by this paper
• Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110α and p110β catalytic subunits of class-Ia phosphoinositide 3-kinases

  2000cited by this paper
• Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma

  1999cited by this paper
• Structure and function of phosphoinositide 3-kinases.

  1998cited by this paper
• PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas

  1998cited by this paper
• The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate*

  1998cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

  1997cited by this paper
• Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide.

  1997cited by this paper
• Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

  1997cited by this paper
• Heterodimeric Phosphoinositide 3-Kinase Consisting of p85 and p110β Is Synergistically Activated by the βγ Subunits of G Proteins and Phosphotyrosyl Peptide*

  1997cited by this paper

• EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge

  2026cites this paper
• Targeting PI3Kβ-dependent cancer with a novel small molecule inhibitor, GT220

  2026cites this paper
• Emerging Trends and Treatment Strategies in Ovarian Cancer: A Comprehensive Review.

  2026cites this paper
• Dual EZH1/2 inhibition enhances DNMT inhibitor efficacy in colon cancer through targeting H3K27me1

  2025cites this paper
• PI3Kβ functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth.

  2025cites this paper
• Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance

  2025cites this paper
• Comprehensive genomic dependency landscape of a human colon cancer organoid

  2025cites this paper
• Network Toxicology and In Vivo Studies Reveal the Toxicity and Mechanisms of Tributyl Citrate Carried by Microplastics in Promoting Colitis-to-Tumorigenesis Transformation

  2025cites this paper
• PI3K-Seeker: A Machine Learning-Powered Web Tool to Discover PI3K Inhibitors

  2025cites this paper
• A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors

  2025cites this paper
• Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems

  2025cites this paper
• Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications

  2025cites this paper
• PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

  2025cites this paper
• PI3Kγ in Tumour Inflammation: Bridging Immune Response and Cancer Progression—A Mini‐Review

  2025cites this paper
• Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With PIK3CA Mutations and Overcoming Strategies

  2025cites this paper
• PI3Kβ moonlights as a protein kinase: driving fatty acid metabolism and histone acetylation in cancer

  2025cites this paper
• Suppression of mTOR Signaling by miR‐302/367 Cluster in Breast Cancer Cells

  2025cites this paper
• Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

  2025cites this paper
• Optimization of IgG1 immune complexes to stimulate cytokine production in innate cells.

  2025cites this paper
• The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

  2025cites this paper
• PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?

  2025cites this paper
• Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition

  2025cites this paper
• Genome-wide association study revealed candidate genes associated with egg-laying time traits in layer chicken

  2025cites this paper
• The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ

  2025cites this paper
• Novel role for PI3Kβ in placental function through regulation of system A amino acid transporter expression, associated with embryonic lethality

  2025cites this paper
• Molecular mechanisms of PI3K isoform dependence in embryonic growth

  2024cites this paper
• Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis

  2024cites this paper
• SP1 Mediated PIK3CB Upregulation Promotes Gastric Carcinogenesis

  2024cites this paper
• PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer

  2024cites this paper
• A defective splicing machinery promotes senescence through MDM4 alternative splicing

  2024influential citation
• USP39 regulates pyruvate handling in non-small cell lung cancer

  2024cites this paper
• THUMPD3 regulates alternative splicing of ECM transcripts in human lung cancer cells and promotes proliferation and migration

  2024cites this paper
• Platelet PI3Kβ regulates breast cancer metastasis

  2024cites this paper
• Molecular Basis of Oncogenic PI3K Proteins

  2024cites this paper
• Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

  2024cites this paper
• Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer

  2024cites this paper
• Deubiquitinase USP9x regulates the proline biosynthesis pathway in non-small cell lung cancer

  2024cites this paper
• Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

  2024cites this paper
• The role of metabolic reprogramming in kidney cancer

  2024cites this paper
• Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers

  2024cites this paper
• Navigating the Complexity of PI3K/AKT Pathway in HER-2 Negative Breast Cancer: Biomarkers and Beyond.

  2024cites this paper
• Integrator Complex Subunit 3 Knockdown Has Minimal Effect on Lytic Herpes Simplex Virus Type-1 Infection in Fibroblast Cells

  2024cites this paper
• Development of small-molecule inhibitors that target PI3Kβ.

  2023cites this paper
• Lamin B Receptor Upregulation in Metastatic Melanoma Causes Cholesterol-Mediated Nuclear Envelope Fragility

  2023cites this paper
• MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms

  2023cites this paper
• New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer

  2023cites this paper
• Nucleic acid drug vectors for diagnosis and treatment of brain diseases

  2023cites this paper
• The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer

  2023cites this paper
• Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.

  2023cites this paper
• Generating a murine PTEN null cell line to discover the key role of p110β-PAK1 in Castration-Resistant Prostate Cancer invasion.

  2023cites this paper
• PI3Kβ controls immune evasion in PTEN-deficient breast tumours

  2023cites this paper
• Enzyme lights dual fires to promote cancer

  2023cites this paper
• Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

  2023cites this paper
• Ultrasound-mediated delivery of Pik3cb shRNA using magnetic nanoparticles for the treatment of in-stent restenosis in a rat balloon-injured model

  2023cites this paper
• Menin Maintains Cholesterol Content in Colorectal Cancer via Repression of LXR-Mediated Transcription

  2023cites this paper
• Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

  2023cites this paper
• Bi-allelic variants in NAE1 cause intellectual disability, ischiopubic hypoplasia, stress-mediated lymphopenia and neurodegeneration.

  2023cites this paper
• Participation of ATM, SMG1, and DDX5 in a DNA Damage-Induced Alternative Splicing Pathway

  2023cites this paper
• Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

  2023cites this paper
• Tetraconazole interrupts mitochondrial function and intracellular calcium levels leading to apoptosis of bovine mammary epithelial cells.

  2023cites this paper
• AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)

  2023cites this paper
• Transcriptome analysis of high mortality phenomena in polyploid fish embryos: An allotriploid embryo case study in hybrid grouper (Epinephelus fuscoguttatus ♀ × Epinephelus lanceolatus ♂)

  2023cites this paper
• Development of PI3Kγ selective inhibitors: the strategies and application

  2023cites this paper
• IRAK2 Downregulation in Triple-Negative Breast Cancer Cells Decreases Cellular Growth In Vitro and Delays Tumour Progression in Murine Models

  2023cites this paper
• Thiazolopyrimidine Scaffold as a Promising Nucleus for Developing Anticancer Drugs: a Review in Last Decade.

  2022cites this paper
• Analysis of the lncRNA–miRNA–mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC

  2022cites this paper
• Suppression of CCT3 Inhibits Tumor Progression by Impairing ATP Production and Cytoplasmic Translation in Lung Adenocarcinoma

  2022cites this paper
• A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

  2022cites this paper
• Gene expression and network based study of colorectal adenocarcinoma reveals tankyrase, PIK3CB and cyclin G-associated kinase as potential target candidates

  2022cites this paper
• Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

  2022cites this paper
• Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.

  2022cites this paper
• Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

  2022cites this paper
• The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review

  2022cites this paper
• PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

  2022cites this paper
• Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy

  2022cites this paper
• GqPCR-stimulated dephosphorylation of AKT is induced by an IGBP1-mediated PP2A switch

  2022cites this paper
• Advances in Polyhydroxyalkanoate Nanocarriers for Effective Drug Delivery: An Overview and Challenges

  2022cites this paper
• Circular RNA Fibroblast Growth Factor Receptor 1 Promotes Pancreatic Cancer Progression by Targeting MicroRNA-532-3p/PIK3CB Axis

  2022cites this paper
• AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

  2022cites this paper
• Class I PI3K Biology.

  2022cites this paper
• Beyond PI3Ks: targeting phosphoinositide kinases in disease

  2022cites this paper
• HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia

  2022cites this paper
• P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

  2022cites this paper
• HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models

  2022cites this paper
• SLIDE-VIP: a comprehensive, cell line- and patient-based framework for synthetic lethality prediction in DNA damage repair, chromatin remodeling and cell cycle

  2022cites this paper
• Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

  2021cites this paper
• Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

  2021cites this paper
• PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

  2021cites this paper
• Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells

  2021cites this paper
• Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent.

  2021cites this paper
• Distinct epithelial-to-mesenchymal transitions induced by PIK3CAH1047R and PIK3CB

  2021cites this paper
• Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

  2021cites this paper
• Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

  2021cites this paper
• SUMOylation modulates the stability and function of PI3K-p110β

  2021cites this paper
• The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma

  2021cites this paper
• Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K

  2021cites this paper
• The role of PI3'‐lipid signalling in melanoma initiation, progression and maintenance

  2021cites this paper
• Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma

  2021cites this paper
• Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers

  2021cites this paper
• AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B.

  2021cites this paper